{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-008521","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.060751+00:00","generated_at":"2026-06-04T13:09:52.498061+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired","bullets":["Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.","R&D expenses $13.1M (up 68% YoY) due to in-use studies and DM199 manufacturing; G&A $8.2M (up 32%).","ReMEDy2 Phase 2/3 trial: 6 U.S. sites open; interim enrollment of 144 patients expected by Q1 2025.","Protocol modified to focus on moderate AIS (NIHSS 5-15) and exclude posterior strokes to boost efficacy.","Appointed Dr. Lorianne Masuoka as CMO in Jan 2024 and Rebekah de Vitry Fries as VP Clinical Operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-008521","json":"https://secwatch.observer/filing/0001437749-24-008521.json","markdown":"https://secwatch.observer/filing/0001437749-24-008521.md","text":"https://secwatch.observer/filing/0001437749-24-008521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/0001437749-24-008521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/dmtp20240318_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:09:52.498061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39a0278ba89572496acd4e1e241ceddf81a8edb3","claim":"DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 19, 2024, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/0001437749-24-008521-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}